Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Trestle

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on Dec 23, 2021 10:23am

309 Views

Post# 34257785

Trestle

Last month THTX contracted Steve Vincze

the founder of Trestle based in Boston. This company offers various services among others the below.

https://www.linkedin.com/in/stevevincze

“We understand the rigors, timing, speed and valuation implications of an effective compliance program due diligence review, whether for a buyer or a seller or for a public or private transaction.

Merger & Acquisition Transactions

Due Diligence

Joint Ventures & Strategic Alliances…”

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland